Felipe Duran
Fortune : 42 449 $ au 30/09/2026
Fortune : 42 449 $ au 30/09/2026
Mr. Felipe Duran is a Chief Financial Officer at iBio, Inc. Mr. Duran was previously employed as a Chief Financial Officer-Lupin Latin America by Lupin Pharmaceuticals, Inc. and a Manager-Financial Planning & Analysis by Noven Pharmaceuticals, Inc. He received his undergraduate degree from the University of Miami and an MBA from the University of Miami.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IBIO, INC. 0,1% | 01/09/2026 | 35 974 ( 0,1% ) | 42 449 $ | 30/09/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| IBIO, INC. | Directeur Financier/CFO | 13/02/2023 |
| Sociétés | Poste | Fin |
|---|---|---|
Lupin Pharmaceuticals, Inc.
Lupin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes generic formulations, biotechnology products & APIs | Directeur Financier/CFO | 01/05/2021 |
Noven Pharmaceuticals, Inc.
Noven Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research, development, manufacture, marketing and sale of transdermal pharmaceutical products | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
Noven Pharmaceuticals, Inc.
Noven Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research, development, manufacture, marketing and sale of transdermal pharmaceutical products | Commercial Services |
University of Miami
University of Miami Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
iBio, Inc.
iBio, Inc. Pharmaceuticals: OtherHealth Technology Engages in the development and commercialization of vaccines and therapeutic proteins | Health Technology |
Lupin Pharmaceuticals, Inc.
Lupin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes generic formulations, biotechnology products & APIs | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national